NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/06/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization188.26 mln
Float31.70 mln
Earnings Date07/15/2026
EPS
2.60
Solid
P / E
1.76
Deeply undervalued
Piotroski F-Score
2
/ 9
Weak
Relative Strength
93
/ 100
Top performer
Debt / Equity
0.00
Debt-free
ROE
58.72
Exceptional
Business Description
Oramed Pharmaceuticals is a New York-based drug development company focused on making it possible for patients to take insulin and other protein-based medicines as a pill rather than an injection. Its leading product, an oral insulin capsule called ORMD-0801, is currently in late-stage clinical trials for people living with diabetes. The company also holds licensing rights to develop oral vaccines targeting COVID-19 and related coronaviruses.
